证券代码：300015 证券简称：爱尔眼科 公告编号：2025-071 爱尔眼科医院集团股份有限公司 关于为控股子公司开具履约保函的公告 2、成立日期：2012 年 6 月 26 日 3、注册地点：韶关市 4、法定代表人：何伟亮 5、注册资本：2000 万元人民币 6、经营范围：内科/儿童保健科；儿童五官保健专业/眼科/医疗美容科/麻醉科/ 医学检验科/医学影像科；超声诊断专业；心电诊断专业******(在许可证有效期内 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 9 月 22 日召开第六届董事会第四十二次会议和第六届监事会第二十七次会议，分别审议 通过了《关于为控股子公司开具履约保函的议案》，同意公司为其控股子公司韶 关爱尔眼科医院有限公司（以下简称"韶关爱尔"）履行工程款支付义务提供担 保，并出具金额不超过人民币 170 万元的履约保函。上述事项无需提交股东大会 审议。现将相关事项说明如下： 一、开具履约保函的概述 公司控股子公司韶关爱尔与施工承包方广东钜能建设有限公司签订了《韶关爱 尔眼科 ...

具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）上刊登的《关于 2021 证券代码：300015 证券简称：爱尔眼科 公告编号：2025-069 爱尔眼科医院集团股份有限公司 第六届监事会第二十七次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）第六届监事会第二十 七次会议于 2025 年 9 月 22 日以通讯表决方式召开，会议通知于 2025 年 9 月 16 日以邮件方式送达，会议由监事会主席宁俊萍女士召集主持，应到监事 3 人，实 到监事 3 人，会议的召开符合《中华人民共和国公司法》（以下简称"《公司法》"） 和《公司章程》的有关规定，会议合法、有效。经审议，本次会议一致通过如下 议案： 一、《关于 2021 年限制性股票激励计划暂缓授予部分第四个解除限售期解 除限售条件成就但股票暂不上市的议案》 公司 2021 年限制性股票激励计划暂缓授予部分第四个解除限售期解除限售 条件达成之日为 2025 年 9 月 22 日；本次符合解除限售条件的激励对象共计 3 名，均满足 100% ...

公司 2021 年限制性股票激励计划暂缓授予部分第四期解除限售条件达成之 日为 2025 年 9 月 22 日；经董事会薪酬与考核委员会认真核查，本次符合解除限 售条件的激励对象共计 3 名，均满足 100%解除限售条件，可解除限售的限制性 股票数量为 198,798 股，占公司目前总股本的 0.0021%；根据公司《2021 年限制 性股票激励计划（草案）》所有激励对象承诺，自每个解除限售的条件达成之日 起 6 个月内，其所持有的当批次解除限售的全部限制性股票不得转让。因此公司 申请本次解除限售的限制性股票暂不上市，继续禁售至 2026 年 3 月 21 日。 此项议案以 7 票同意、0 票反对、0 票弃权获得通过。 该项议案已经董事会薪酬与考核委员会审议通过。 具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）上刊登的《关于 2021 年限制性股票激励计划暂缓授予部分第四个解除限售期解除限售条件成就但股 票暂不上市的公告》。 证券代码：300015 股票简称：爱尔眼科 公告编号：2025-068 爱尔眼科医院集团股份有限公司 第六届董事会第四十二次会议决议公告 本公司及董事会全体成员保证公 ...

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The growth of healthcare expenses, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating that commercial health insurance may provide a solution to the pressures faced by the medical insurance system [3][15] - The commercial health insurance sector is expected to grow significantly, with premiums projected to reach 97.74 billion yuan by 2024, driven by low penetration rates and the need for additional funding sources [20][24] - Policies are increasingly supportive of commercial health insurance, particularly in relation to innovative drugs, which are now being included in the commercial health insurance directory [71][76] Summary by Sections Part 1: Healthcare Financing System - The healthcare financing system in China consists of government, social, and personal contributions, with social contributions being the main driver for future growth [10][15] Part 2: Growth of Health Insurance - The commercial health insurance market is expected to fill a significant funding gap, with an estimated shortfall of over 1.7 trillion yuan by 2030 [21][22] - Medical insurance is the primary source of compensation within commercial health insurance, with a compensation rate of approximately 68.79% in 2022 [27][31] Part 3: Core Products of Medical Insurance - The report highlights the importance of medical insurance as a key focus area, noting that it directly compensates for medical expenses, unlike critical illness insurance [31][35] Part 4: Policy Support for Health Insurance Development - A series of policies since 2009 have aimed to promote the development of commercial health insurance, with specific targets for market size and coverage [71][72] Part 5: Investment Recommendations - The report suggests focusing on innovative drug companies with rich pipelines, DTP pharmacies, and companies in the TPA industry, as well as innovative medical devices and high-end medical service providers [77]

Core Viewpoint - Aier Eye Hospital has been awarded the "2025 Future Health Industry Star Listed Company" for its continuous technological innovation and outstanding market performance, reflecting its commitment to the eye health sector and alignment with national development strategies [1] Group 1: Company Achievements - In the first half of 2025, Aier Eye Hospital achieved an outpatient volume of 9.2483 million, a year-on-year increase of 16.47%, and a surgical volume of 879,000, up 7.63% year-on-year, indicating strong demand for its eye care services [2] - The company has established a tiered chain model of hospitals to address uneven distribution of medical resources, enhancing access to high-quality eye health services across urban and rural areas in China [1] Group 2: Technological Innovation - Aier Eye Hospital has built an integrated innovation platform for medical education and research, supporting talent cultivation from undergraduate to doctoral levels, and focusing on innovative technologies to improve eye health services for disadvantaged groups [2] - The company has launched a "Digital Ophthalmology" development model, collaborating with the Chinese Academy of Sciences to establish a digital eye research institute and develop advanced diagnostic technologies [3] Group 3: Quality and Safety Management - The company prioritizes medical quality and safety management, implementing a comprehensive quality management system and enhancing risk prevention measures to ensure high-quality healthcare delivery [3] - Aier Eye Hospital aims to synchronize its medical technology, equipment, and pharmaceuticals with international standards, facilitating the global dissemination of innovative technologies [3] Group 4: Future Directions - Aier Eye Hospital plans to continue strengthening its technological innovation and digital capabilities, striving to make advancements in ophthalmology accessible to all patients and working towards becoming a world-class eye medical center [4] - The company is committed to its mission of ensuring eye health rights for all individuals, regardless of their socio-economic status [4]

Market Performance - The Medical Health Index (980016) closed at 7021.34 points, down 1.08%, with a trading volume of 33.906 billion yuan and a turnover rate of 1.07% [1] - Among the index constituents, 5 stocks rose while 45 stocks fell, with Yirui Technology leading the gainers at 1.82% and Changchun High-tech leading the decliners at 3.91% [1] Key Constituents - The top ten constituents of the Medical Health Index include: - WuXi AppTec (13.58% weight) at 108.75 yuan, up 1.23% with a market cap of 320.976 billion yuan - Hengrui Medicine (10.87% weight) at 69.65 yuan, down 2.03% with a market cap of 462.281 billion yuan - Mindray Medical (8.17% weight) at 235.00 yuan, down 1.18% with a market cap of 284.924 billion yuan - United Imaging Healthcare (4.14% weight) at 147.90 yuan, down 1.40% with a market cap of 121.893 billion yuan - Other notable constituents include Pianzai Shou, Yier Eye Hospital, Kelun Pharmaceutical, Xinhecheng, Fosun Pharma, and Yixiao Aoshi [1] Capital Flow - The Medical Health Index constituents experienced a net outflow of 2.29 billion yuan from institutional investors, while retail investors saw a net inflow of 2.013 billion yuan [3] - Notable capital flows include: - Mindray Medical with a net inflow of 98.789 million yuan from institutional investors and a net outflow of 10.5 million yuan from speculative funds - Changchun High-tech with a net inflow of 67.986 million yuan from institutional investors and a significant net outflow from speculative funds [3]

Core Viewpoint - The aging population in China is driving the demand for presbyopia correction technologies, which include optical correction, surgical correction, and drug treatment. The industry is witnessing rapid development, with both public and private healthcare institutions expanding their services in this area [1][3][4]. Industry Overview - The prevalence of presbyopia treatment methods in China is currently low, indicating that the market is still in its early stages, presenting significant growth potential [3][5]. - The aging population is expected to reach over 400 million by 2035, with more than 40% of the population being elderly by mid-century, leading to an increase in age-related eye diseases [3][4]. Company Developments - 德视佳 reported a 2.8% increase in revenue from presbyopia treatments, reaching 121.4 million HKD in the first half of 2025, while revenue from Presbyond treatment rose from 1.2 million HKD in 2024 to 3.6 million HKD [2][6]. - 爱尔眼科 achieved a revenue of 11.507 billion CNY in the first half of 2025, a 9.12% year-on-year increase, with a net profit of 2.051 billion CNY, reflecting a 0.05% growth [6][7]. - 爱尔眼科 is actively promoting awareness and education regarding presbyopia treatments, anticipating significant market growth driven by the increasing payment capacity and quality demands of the aging population [6][7]. Market Dynamics - The demand for presbyopia treatments is expected to continue rising, with the three-focus lens replacement surgery being identified as the most effective method for addressing this condition [7]. - Despite a decline in net profit for 德视佳 in the first half of 2025, the company remains optimistic about the presbyopia treatment market, viewing it as a key growth driver even in challenging economic conditions [7].

天眼查工商信息显示，上海爱尔清亮眼科医院有限公司，成立于2019年，位于上海市，是一家以从事卫 生为主的企业。企业注册资本3500万人民币，实缴资本2450万人民币。 其股东信息显示，湖南亮视视界医疗产业管理合伙企业(有限合伙)持股70%，为第一大股东。爱尔眼科 （300015）医院集团股份有限公司(简称"爱尔眼科"，300015.SZ)直接持股0.2857%，间接持股比例 13.65%。 中国经济网北京9月19日讯信网17日报道《上海爱尔清亮眼科医院因违规收费被罚》显示，上海爱尔清 亮眼科医院有限公司因存在重复收费和分解项目收费的违规行为，被上海市青浦区医疗保障局处罚。 行政处罚决定书(青医保罚决字第2220250122号)显示，上海爱尔清亮眼科医院有限公司因在医疗服务中 存在重复收费和分解项目收费的行为，违反了《医疗保障基金使用监督管理条例》(国务院令第735号) 第三十八条第三项的规定。上海市青浦区医疗保障局依据《医疗保障基金使用监督管理条例》(国务院 令第735号)第三十八条相关规定，对上海爱尔清亮眼科医院有限公司处以34303元罚款。 ...

人民财讯9月19日电，有投资者在互动平台向爱尔眼科（300015）提问：从2021年到现在四年时间公司 业绩停滞不前，公司未来的增长点在哪里？爱尔眼科回复，经济环境和外部因素对眼科行业有一定影 响，但透过浮沫看潜流，眼科市场空间实际上在逐步扩大。一方面，眼疾病及视力损伤患者群体基数庞 大，目前各亚专科诊疗渗透率偏低。另一方面，近视人群居高不下，人口老龄化程度持续加深，白内 障、老视、干眼症等年龄相关性眼病持续增长。公司加快业务创新，促进各学科全面发展，推动诊疗量 不断增长。 ...

Core Insights - The Medical Health Index (980016) closed at 7114.13 points on September 17, with a slight increase of 0.22% and a trading volume of 34.146 billion yuan, indicating a turnover rate of 1.06% [1] Group 1: Index Performance - Among the constituent stocks of the Medical Health Index, 18 stocks rose while 30 stocks fell on the same day [1] - Bai Li Tian Heng led the gains with a rise of 4.08%, while Junshi Biosciences recorded the largest decline at 2.52% [1] Group 2: Top Constituents - The top ten constituents of the Medical Health Index are as follows: - WuXi AppTec (603259) with a weight of 13.58%, latest price at 109.29 yuan, and a market cap of 322.57 billion yuan, increased by 2.09% [1] - Hengrui Medicine (600276) with a weight of 10.87%, latest price at 70.13 yuan, and a market cap of 465.47 billion yuan, increased by 1.42% [1] - Mindray Medical (300760) with a weight of 8.17%, latest price at 66.66 yuan, and a market cap of 290.25 billion yuan, decreased by 0.09% [1] - United Imaging Healthcare (688271) with a weight of 4.14%, latest price at 151.60 yuan, and a market cap of 124.94 billion yuan, decreased by 0.90% [1] - Other notable constituents include Pianzai Shou (600436), Aier Eye Hospital (300015), and Fosun Pharma (600196) [1] Group 3: Capital Flow - The Medical Health Index constituents experienced a net outflow of 601 million yuan from major funds, while retail investors saw a net inflow of 615 million yuan [1] - Detailed capital flow for major stocks indicates that WuXi AppTec had a net inflow of 4.28 million yuan from major funds, while Hengrui Medicine saw a net outflow of 3.43 million yuan [2]